Chemotherapy-induced nausea and vomiting in routine practice: a European perspective

Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811?819

Aapro MS (2002) How do we manage patients with refractory or breakthrough emesis? Support Care Cancer 10:106?109

ASHP (1999) Therapeutic Guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56:729?764

Barrenetxea G, Schneider J, Centeno MM, et al (1996) Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens. Cancer Chemother Pharmacol 38:471?475

Bender CM, McDaniel RW, Murphy-Ende K, et al (2002) Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 6:94?102

Bliss JM, Robertson B, Selby PJ (1992) The effect of nausea and vomiting upon quality of life measures. Brit J Cancer 66:14S?23S

Borjeson S, Hursti TJ, Peterson C, et al (1997) Similarities and differences in assessing nausea and vomiting on a verbal category scale and a visual analogue scale. Cancer Nurs 20:260?266

Cocquyt V, Van Belle S, Reinhardt RR, et al (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754?030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835?842

Cubeddu LX (1996) Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 53 [Suppl 1]:18?25

du Bois A, Kriesinger-Schroeder H, Meerpohl HG (1995) The role of serotonin as a mediator of emesis induced by different stimuli. Support Care Cancer 3:285?290

Farley PA, Dempsey CL, Shillington AA, et al (1997) Patients? self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health Syst Pharm 54:2478?2482

Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971?2994

Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 55:173?189

Griffin AM, Butow PN, Coates AS, et al (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189?195

Grunberg SM, Osoba D, Hesketh PJ, et al (2004) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity?an update. Support Care Cancer (in press)

Havsteen H, Kjaer M (1991) Double-blind randomized cross-over trial comparing methylprednisolone with placebo in chemotherapy-induced nausea and vomiting: a study with special reference to efficacy parameters. Anticancer Drugs 2:571?579

Hollander M, Wolfe DA (1998) Nonparametric Statistical Methods. Wiley, New York

Homesley HD, Gainey JM, Jobson VW, et al (1982) Cisplatin chemotherapy and emesis in patients given metoclopramide and controls. N Engl J Med 307:250

Koeller JM, Aapro MS, Gralla RJ, et al (2002) Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10:519?522

Kris MG, Gralla RJ, Clark RA, et al (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of cisplatin. J Clin Oncol 3:1379?1384

Kris MG, Pisters KM, Hinkley L (1994) Delayed emesis following anticancer chemotherapy. Support Care Cancer 2:297?300

Kris MG, Radford J, Pizzo BA, et al (1997) Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 89:817?818

Lindley CM, Hirsch JD (1992) Nausea and vomiting and cancer patients? quality of life: a discussion of Professor Selby?s paper. Br J Cancer Suppl 19:S26?S29

Lindley CM, Hirsch JD, O?Neill CV, et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331?340

Markman M (2002) Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med 69:609?610, 612, 615?617

Martin AR, Cai B, Pearson J, et al (2001) Patient-assessed impact of chemotherapy-induced nausea on daily life: how much is too much? Oncol Nurs For 28:338

McCune JS, Oertel MD, Pfeifer D, et al (2001) Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study. Ann Pharmacoth 35:14?20

Morrow GR, Hickok JT, Burish TG, et al (1996) Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 19:199?203

Muth ER, Stern RM, Thayer JF, et al (1996) Assessment of the multiple dimensions of nausea: the Nausea Profile (NP). J Psychosom Res 40:511?520

Navari RM, Reinhardt RR, Gralla RJ, et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor-antagonist. L-754,030. Antiemetic Trials Group. N Engl J Med 340:190?195

NCCN antiemesis practice guidelines (1997) Oncology 11:57?89

Osoba D, Zee B, Warr D, et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5:307?313

Ossi M, Anderson E, Freeman A (1996) 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology 53 suppl 1:78?85

Rizk AN, Hesketh PJ (1999) Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development. Drugs R D 2:229?235

Roila F, Donati D, Tamberi S, Margutti G (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88?95

Roscoe JA, Hickok JT, Morrow GR (2000) Patient expectations as predictor of chemotherapy-induced nausea. Ann Behav Med 22:121?126

Roscoe JA, Morrow GR, Hickok JT, et al (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113?21

Uyl-de Groot CA, Wait S, Buijt I (2000) Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. Eur J Cancer 36:522?535